Project Grant N629091912137

This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program totaling $100,000 will support research to develop next-generation clustered regularly interspaced short palindromic repeat (CRISPR) systems for curing inherited diseases. Specifically, the awardee, the University of California, Berkeley, will work to circumvent in vivo delivery challenges with CRISPR-Cas9 by developing miniature RNA-guided genome editors smaller than Cas9 that can be...

This $653,880 Project Grant awarded by the National Human Genome Research Institute (NHGRI) under the Human Genome Research program (CFDA 93.172) supports the development of a high-content, image-based CRISPR screening platform to discover regulators of three-dimensional (3D) genome architecture across multiple length scales. The goal is to advance screening technology to enable large-scale, multi-omic analysis of the spatial organization of the genome, nucleome, and transcriptome. Key...

This Project Grant award from the USDA National Institute of Food and Agriculture under the Biotechnology Risk Assessment Research (BRAG) program (CFDA 10.219) provides $649,414 to the University of California, San Diego (UCSD) to develop tools and technologies for monitoring and improving the use of precision-guided sterile insect technique (PGSIT) and other CRISPR-based genetic technologies to control the spotted wing drosophila pest. Key deliverables include: A diagnostic system called...

This $509,070 Project Grant award from the National Science Foundation's Division of Molecular and Cellular Biosciences (CFDA 47.074 Biological Sciences) supports research at Purdue University to explore the working mechanism of CRISPR-Cas12 endonucleases and analogues. The primary goals are to investigate the regulatory mechanisms of natural CRISPR inhibitor proteins, and to dissect the structural dynamics of newly identified Cas12 analogues found in mobile genetic elements and viruses. This...

This National Science Foundation Project Grant of $180,493 will support the development of an ultrasensitive point-of-care diagnostic system using clustered regularly interspaced short palindromic repeats (CRISPR) technology for early disease detection without pre-amplification of viral genomes. Funded under the NSF's Office of Integrative Activities program (CFDA 47.083), which enhances STEM competitiveness through capacity building and broadening participation, this 24-month project will...

This $3,314,560 Cooperative Agreement award, funded by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), aims to develop CRISPR-Cas-based gene editing therapies for two types of dominant genetic hearing loss, DFNA41 and DFNA2. The award recipient, Massachusetts Eye and Ear Infirmary, will conduct IND-enabling studies, including evaluating off-target effects, efficacy in animal models, and safety in non-human primates. The...

This $117,074 Project Grant award from the National Science Foundation's (NSF) Mathematical and Physical Sciences program (CFDA 47.049) supports research at Lehigh University to develop biomaterial-guided CRISPR gene editing delivery systems. The key objectives are to: Determine how peptide-based nanoparticle formulation and properties impact CRISPR ribonucleoprotein (RNP) uptake, activity, and functionality. Investigate how material charge and porosity control the temporal action of CRISPR...

The Massachusetts General Hospital will receive $3,024,000 through a three-year Project Grant from the National Institutes of Health Trans-NIH Research Support program to develop scalable methods for engineering and characterizing novel CRISPR-associated protein variants. The goal is to address limitations of current CRISPR-Cas enzymes by optimizing machine learning-guided directed evolution to create a catalog of customizable DNA editors with improved properties like expanded target...

The federal Project Grant award ID R43HG014080 was provided by the National Human Genome Research Institute (CFDA 93.172 Human Genome Research) to Jumpcode Genomics Inc., a for-profit company based in San Diego, California. The $383,748 grant, awarded on March 3, 2025, supports the development of a CRISPR-based depletion technology to improve the accuracy of next-generation sequencing (NGS) genetic testing, particularly for newborn screening. The goal is to resolve ambiguity in variant calling...

The National Institute of Neurological Disorders and Stroke (NINDS), through the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), has awarded a $869,959 Cooperative Agreement to The Regents of the University of California, San Francisco to develop a safe and effective genome editing therapy to treat frontotemporal dementia caused by the C9ORF72 gene mutation. The project aims to optimize a CRISPR/Cas9 genome editing strategy to excise the C9ORF72 repeat...